Mr. Cumbo has served as Solid’s President and Chief Executive Officer and as a director since December 2022.
Mr. Cumbo served as the President and Chief Executive Officer and member of the Board of directors for AavantiBio from October 2020 until December 2022.
From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics, Inc., a precision genetic medicine company, ultimately serving as Executive Vice President, Chief Commercial Officer. From 2011 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex, launching Incivek, a treatment for hepatitis C, and from 2010 to 2011, he served as Area director for Vertex. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV and cardiovascular franchises at Gilead Sciences, Inc., a biopharmaceutical company.
Mr. Cumbo has served on the Board of Directors of Verve Therapeutics, Inc. since June 2022. Mr. Cumbo previously served on the Board of Directors of RA Pharmaceuticals, Inc., a clinical stage biopharmaceutical company acquired by UCB, Brussels, from November 2018 to April 2020.
Mr. Cumbo received a Bachelor of Science in Laboratory Technology from Auburn University.
What is Alexander Cumbo's net worth?
The estimated net worth of Alexander Cumbo is at least $481.82 thousand as of December 3rd, 2025. Mr. Cumbo owns 81,388 shares of Solid Biosciences stock worth more than $481,817 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Cumbo may own. Additionally, Mr. Cumbo receives an annual salary of $918,550.00 as President & CEO at Solid Biosciences. Learn More about Alexander Cumbo's net worth.
How old is Alexander Cumbo?
What is Alexander Cumbo's salary?
How do I contact Alexander Cumbo?
Has Alexander Cumbo been buying or selling shares of Solid Biosciences?
During the last quarter, Alexander Cumbo has sold $55,228.88 in Solid Biosciences stock. Most recently, Alexander Cumbo sold 10,808 shares of the business's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $5.11, for a transaction totalling $55,228.88. Following the completion of the sale, the chief executive officer now directly owns 81,388 shares of the company's stock, valued at $415,892.68. Learn More on Alexander Cumbo's trading history.
Who are Solid Biosciences' active insiders?
Are insiders buying or selling shares of Solid Biosciences?
During the last twelve months, Solid Biosciences insiders bought shares 1 times. They purchased a total of 1,860 shares worth more than $9,932.40. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 31,092 shares worth more than $155,239.01. The most recent insider tranaction occured on December, 3rd when COO David T Howton sold 4,932 shares worth more than $25,202.52. Insiders at Solid Biosciences own 1.9% of the company.
Learn More about insider trades at Solid Biosciences. Information on this page was last updated on 12/3/2025.
